Juratli et al. [40] used ddPCR to demonstrate that TERT mutations can be detected in the CSF of GBM patients with a specificity of 100% and a sensitivity of 92.1%, indicating its use as a diagnostic and prognostic biomarker, as well as a biomarker for therapeutic response. This evidence concerns the gene TERT and glioblastoma.